Vascular Biogenics Financials
VBLTDelisted Stock | USD 0.28 0.01 3.45% |
Vascular |
Please note, the imprecision that can be found in Vascular Biogenics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vascular Biogenics. Check Vascular Biogenics' Beneish M Score to see the likelihood of Vascular Biogenics' management manipulating its earnings.
Vascular Biogenics Stock Summary
Vascular Biogenics competes with Revelation Biosciences, Zura Bio, Phio Pharmaceuticals, ZyVersa Therapeutics, and Transcode Therapeutics. Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | IL0011327454 |
Business Address | 8 HaSatat Street, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.vblrx.com |
Phone | 972 8 993 5000 |
Currency | USD - US Dollar |
Vascular Biogenics Key Financial Ratios
Return On Equity | -0.6 | |||
Return On Asset | -0.29 | |||
Target Price | 5.0 | |||
Beta | 0.71 | |||
Z Score | -2.01 |
Vascular Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Vascular Biogenics's current stock value. Our valuation model uses many indicators to compare Vascular Biogenics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vascular Biogenics competition to find correlations between indicators driving Vascular Biogenics's intrinsic value. More Info.Vascular Biogenics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Vascular Biogenics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Vascular Biogenics Market Pulse
Quote | 0.28 |
Change(%) | 3.45 |
Change | 0.01 |
Open | 0.29 |
Low | 0.28 |
High | 0.3 |
Volume | 0 |
Exchange | NASDAQ |
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Vascular Biogenics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Vascular has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Vascular Biogenics' financials are consistent with your investment objective using the following steps:- Review Vascular Biogenics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Vascular Biogenics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Vascular Biogenics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Vascular Biogenics' stock is overvalued or undervalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |